Drug Profile
Enoxaparin sodium biosimilar - Techdow Pharmaceuticals
Alternative Names: InhixaLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Techdow Pharmaceuticals
- Class Anti-ischaemics; Antithrombotics; Ischaemic heart disorder therapies; Low molecular weight heparins
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Deep vein thrombosis; Myocardial infarction; Unstable angina pectoris; Venous thromboembolism
Most Recent Events
- 21 Jul 2016 Preregistration for Deep vein thrombosis in European Union (SC) before July 2016
- 21 Jul 2016 Preregistration for Myocardial infarction (acute ST segment elevation myocardial infarction) in European Union (SC, 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL) before July 2016
- 21 Jul 2016 Preregistration for Unstable angina pectoris (Combination therapy) in European Union (SC) before July 2016